Human iPS Cells in Disease Modelling
Human iPS cells have a great potential to be cell sources for regenerative medicine because of the promise of infinite self-renewal and the capability to differentiate into multiple cell types. This book focuses on another great potential of human iPS cel
- PDF / 2,329,000 Bytes
- 102 Pages / 439.43 x 683.15 pts Page_size
- 77 Downloads / 217 Views
Human iPS Cells in Disease Modelling
123
Human iPS Cells in Disease Modelling
ThiS is a FM Blank Page
Keiichi Fukuda Editor
Human iPS Cells in Disease Modelling
Editor Keiichi Fukuda Department of Cardiology Keio University School of Medicine Tokyo, Japan
ISBN 978-4-431-55964-1 ISBN 978-4-431-55966-5 DOI 10.1007/978-4-431-55966-5
(eBook)
Library of Congress Control Number: 2016936099 # Springer Japan 2016 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer Japan KK
Preface
Recent advances in stem cell biology have enabled us to examine the regeneration of various tissues and organs. One of the biggest advances in this field is the induced pluripotent stem cell (iPS cell), which was developed by Shinya Yamanaka in 2006. The iPS cell was a tailor-made multipotent stem cell, and was generated by transfection of the combination of several embryonic stem (ES) cell-specific transcription factors such as Oct3/4, Sox2, and Klf4. It has pluripotency, and can differentiate into various types of cells such as ES cells. Because the iPS cells maintained all the genome information including HLA, it cannot be immunerejected when its derived cells are transplanted to the host. In 2014, the first clinical trial was performed by Masayo Takahashi in patients with senile macular degeneration using autologous iPS cell-derived retinal pigmented cells. Other clinical trials are now being conducted in diverse ways including the cornea, Parkinson’s Disease, spinal cord injury, platelet production, and severe congestive heart failure. Realization of these projects has been eagerly awaited by patients with severe intractable diseases. It was also expected that iPS cells could be used in another field: disease modelling. Hereditary diseases are caused by genome mutations, but their clinical phenotypes, severity, onset, and treatment show wide variation. Mouse models of human d
Data Loading...
